Inovio Pharmaceuticals Stock Soars 9% After Passive Stake Disclosure

Warrant shares made up much of the reported holding as the DNA-medicine developer prepares to launch its newly approved treatment.

Share
Inovio Pharmaceuticals Stock Soars 9% After Passive Stake Disclosure

Inovio Pharmaceuticals, which develops DNA medicines, soared 8.6% to $1.52 in Tuesday trading, as of 10:31 AM ET, adding $22 million in market value. The rise followed investment adviser ADAR1's passive stake disclosure on Monday, reporting about 7% of the common-stock class as of June 30.

Warrants Dominate The Reported Holding

ADAR1's managed funds and accounts held 2,143,910 common shares. Another 4,285,714 warrant shares made up the rest of its reported holding; warrants give holders the right to buy shares.

The reporting parties certified that they held the securities in the course of ordinary business and did not intend to change or influence Inovio's control.

Inovio was on pace for its third gain of 7% or more this month on Tuesday, with a total market value of about $285 million. Shares were still down 19% for the year through Monday's close, against a 9% gain for the S&P 500, despite rising 41% over the previous month.

VOCERYQ Moves Toward Launch

Inovio received accelerated FDA approval for VOCERYQ on October 30, 2026, according to its earnings release last Tuesday. Previously called INO-3107, the treatment is approved to reduce surgery frequency in adults with recurrent respiratory papillomatosis, a rare disease that causes airway growths.

VOCERYQ is used with Inovio's CELLECTRA 5PSP delivery device. The company's medicines use small circular DNA molecules to instruct cells to make proteins, while CELLECTRA devices use brief electrical pulses to deliver them into cells.

“INOVIO is now a commercial stage company with a primary goal to establish VOCERYQ as the preferred first-line immunotherapy for RRP patients,” Jacqueline Shea, Inovio's president and chief executive officer, said in the release, describing its commercial stage transition.

The approval drew on a study of 32 adults. Its measure of complete response was no need for surgery during the 12 months after treatment. Inovio expects a confirmatory study to verify clinical benefit, with a draft protocol due to the FDA before year-end and a final protocol targeted for mid-2027.

The company expects orders and shipments to begin approximately 60 days after approval, with a full commercial launch in the first quarter of 2027. It expects inventory and capacity to cover at least the first launch year through 2027, and has engaged Syneos Health to help recruit and deploy medical and commercial field teams.

Launch Funding Extends The Runway

Inovio reported third-quarter revenue of $298,901 and a $49.2 million net loss. Its recently completed public offering brought in $80.5 million in net proceeds to support commercialization.

Inovio estimates its cash and short-term investments will fund operations into late fourth quarter 2027. That forecast includes the offering proceeds, $10.9 million from warrant exercises after September 30 and an estimated $21 million in operational cash burn for the fourth quarter of 2026.

The runway estimate excludes expected VOCERYQ sales beginning in 2027 and any additional fundraising.

Inovio plans to apply for conditional approval of VOCERYQ in Europe before the end of 2026.

Sources

More on Inovio Pharmaceuticals

All Inovio Pharmaceuticals (INO) coverage →